A dendritic cell multitasks to tackle cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed.

1. Nanocollision promotes locomotion of dendritic cells for tumor therapy.Science advances · 2026
   Article
2. TGFβ1 and SMAD3 Expression Are Associated With Survival After the Immune Checkpoint Inhibitor Therapy for Small Cell Lung Cancer.Cancer reports (Hoboken, N.J.) · 2025
   Article
3. Peripheral CD4 memory T cells predict the efficacy of immune checkpoint inhibitor therapy in patients with non-small cell lung cancer.Scientific reports · 2023
   Observational
4. Endogenous/Exogenous Nanovaccines Synergistically Enhance Dendritic Cell-Mediated Tumor Immunotherapy.Advanced healthcare materials · 2023
   Article
5. The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy.Journal of experimental & clinical cancer research : CR · 2022
   Review
6. Generation ofActa pharmaceutica Sinica. B · 2022
   Article
7. Understanding the functional inflammatory factors involved in therapeutic response to immune checkpoint inhibitors for pan-cancer.Frontiers in pharmacology · 2022
   Review
8. The Role of Long Non-Coding RNAs in the Tumor Immune Microenvironment.Frontiers in immunology · 2022
   Review
9. Overcoming biological barriers to improve solid tumor immunotherapy.Drug delivery and translational research · 2021
   Review
10. Targeting the extracellular matrix for immunomodulation: applications in drug delivery and cell therapies.Drug delivery and translational research · 2021
    Review
11. DCision-making in tumors governs T cell anti-tumor immunity.Oncogene · 2021
    Review

Corrections and comments

• Comment on
  cDC1 prime and are licensed by CD42020

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as